A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

NCT07221669 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Muscular Atrophy, Spinal

Interventions

DRUG: Salanersen

Sponsor

Biogen